Acurx Pharmaceuticals
ACXP
16 hedge funds and large institutions have $247K invested in Acurx Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 2 reducing their positions, and 18 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 2
3.44% more ownership
Funds ownership: 0.56% → 4% (+3.4%)
50% less funds holding
Funds holding: 32 → 16 (-16)
81% less capital invested
Capital invested by funds: $1.33M → $247K (-$1.08M)
83% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$80.4K |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
+$44K |
| 3 |
PFS
Prospect Financial Services
Melville,
New York
|
+$30.4K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
+$27.8K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5.24K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$551K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$74.8K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$74.4K |
| 4 |
Renaissance Technologies
New York
|
-$44.8K |
| 5 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
-$43K |
ACXP Hedge Fund Activity: Q3 2025 in Review
16 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Acurx Pharmaceuticals (ACXP) for Q3 2025, worth a combined $247K — down 81% from $1.33M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of ACXP and 3 opened new positions — a net loss of 15 holders — while 2 trimmed existing stakes and 8 added.
The largest buyer was Susquehanna International Group, adding an estimated $80.4K. The largest seller was Armistice Capital, exiting entirely with an estimated $551K sold.
- 16 institutional investors held Acurx Pharmaceuticals (ACXP) as of Q3 2025, down from 32 in Q2 2025.
- Funds reported $247K of Acurx Pharmaceuticals stock for Q3 2025, down 81% quarter-over-quarter.
- 3 funds opened new Acurx Pharmaceuticals positions in Q3 2025 and 18 closed out, a net change of -15 holders.
- The largest Acurx Pharmaceuticals buyer in Q3 2025 was Susquehanna International Group, an estimated $80.4K added.
- The largest Acurx Pharmaceuticals seller in Q3 2025 was Armistice Capital, an estimated $551K sold.
Based on aggregated 13F filings for Q3 2025.